
About ENSC
Bearish Sentiment
How do you feel about ENSC?
Ensysce Biosciences investors are intensely debating the company's compliance status following Nasdaq granting a second 180-day grace period, while heavily discussing the recent Cy Biopharma acquisition, insider buying by Chairman Bob Gower, financing dilution risks, and upcoming clinical catalysts amid sharp divisions between bullish and bearish sentiments.